OncoCyte (OCX) Scheduled to Post Earnings on Tuesday

OncoCyte (NASDAQ:OCX) is scheduled to be releasing its earnings data after the market closes on Tuesday, November 12th.

OncoCyte (NASDAQ:OCX) last announced its earnings results on Thursday, August 8th. The company reported ($0.36) EPS for the quarter. The firm had revenue of $0.10 million for the quarter. OncoCyte had a negative return on equity of 149.88% and a negative net margin of 3,558.46%.

OncoCyte Stock Down 2.7 %

Shares of NASDAQ OCX opened at $2.84 on Thursday. OncoCyte has a 1 year low of $2.08 and a 1 year high of $4.34. The stock has a fifty day moving average price of $3.06 and a two-hundred day moving average price of $2.96.

Insider Activity at OncoCyte

In other news, major shareholder Broadwood Partners, L.P. bought 1,315,339 shares of the company’s stock in a transaction dated Wednesday, October 2nd. The shares were acquired at an average cost of $2.95 per share, with a total value of $3,880,250.05. Following the completion of the transaction, the insider now directly owns 6,244,405 shares in the company, valued at approximately $18,420,994.75. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In other OncoCyte news, major shareholder Broadwood Partners, L.P. bought 1,315,339 shares of the firm’s stock in a transaction dated Wednesday, October 2nd. The stock was acquired at an average price of $2.95 per share, with a total value of $3,880,250.05. Following the completion of the transaction, the insider now directly owns 6,244,405 shares in the company, valued at approximately $18,420,994.75. This represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Andrea S. James purchased 33,670 shares of the company’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were acquired at an average cost of $2.97 per share, for a total transaction of $99,999.90. Following the completion of the transaction, the chief financial officer now directly owns 33,670 shares of the company’s stock, valued at $99,999.90. The disclosure for this purchase can be found here. 1.58% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have commented on OCX shares. StockNews.com initiated coverage on shares of OncoCyte in a research report on Saturday, November 2nd. They issued a “sell” rating on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $4.25 target price on shares of OncoCyte in a report on Tuesday, October 15th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, OncoCyte has an average rating of “Hold” and a consensus price target of $4.06.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.